Keratoconus is a corneal disease of the eye, which causes a conical distortion in its shape, as a consequence of the progressive partial or total loss of vision which may even reach blindness.
A relatively new non-invasive treatment of the disease has become widely accepted by the global ophthalmological community because, as it seems, it stabilizes the structure of the cornea and ultimately slows down the reduction of vision. This method is constantly evolving and is called CXL (Corneal Crosslinking with Riboflavin).
Through laboratory and clinical tests, it has been shown to strengthen the internal structure of the cornea by stabilizing its entire architecture and in particular by strengthening the linkages between the corneal collagen fibers, which are one of the essential components of maintaining its structure.
CXL treatment can be done in the clinic and lasts about 30 minutes. During this period, drops of "Riboflavin" (Vitamin B2) are instilled, which are subsequently "activated" using ultraviolet radiation.
In the Emmetropia on Tuesday, 19/09/06, the first successful CXL surgery in Crete was performed in a patient suffering from a progressive form of keratoconus, giving hope to many Greek patients for a successful and non-invasive treatment of the keratoconus.